← Eichor
Study identifier: NCT07446647 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Comparative Analysis of Biotinylated, Irradiated and 51-Chromium Radiolabeled Red Blood Cells for Analysis of Recovery and Survival After Autologous Transfusion

Condition: Healthy Volunteer Red Blood Cell Labeling Study; Not Disease Focused  ·  Sponsor: Jose Cancelas

PhasePhase 1
Planned participants20
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersYes

About this study

This research is being done to compare the red blood circulation survival in healthy adult volunteers between the 51 chromium (51Cr) red blood cell (RBC) labeling method and the Biotin (BioRBC) red blood cell (RBC) labeling method to determine if biotinylated red blood cells (BioRBC) is an acceptable non radioactive alternative to 51 chromium (51Cr) radiolabeling for regulatory pharmacokinetic studies of red blood cell products.

This description comes directly from the study's public registry record.

Talk to the study team

Jose A Cancelas-Perez, MD, PhD  ·  617-632-3446  ·  jose_cancelas-perez@dfci.harvard.edu

Always discuss trial participation with your own doctor first.

Locations (2)

Hoxworth Blood Center, University of CincinnatiCincinnati, Ohio, United StatesRecruiting
American Red CrossNorfolk, Virginia, United StatesNot Yet Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07446647